⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16243426 | 0.81 | NFE2L2 (0.38) | — | |
| SCHEMBL3302772 | 0.79 | TP53 (0.65) | — | |
| SCHEMBL21847980 | 0.79 | PTGS1 (0.69) | — | |
| SCHEMBL1795130 | 0.79 | PTGS1 (0.69) | — | |
| SCHEMBL1795132 | 0.79 | PTGS1 (0.69) | — | |
| SCHEMBL1005454 | 0.77 | — | — | |
| SCHEMBL23457950 | 0.75 | TP53 (0.60) | — | |
| SCHEMBL679453 | 0.75 | TP53 (1.00) | — | |
| SCHEMBL711415 | 0.75 | — | — | |
| SCHEMBL1179749 | 0.75 | RELA (0.74) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
| CN-112775823-B | Polishing pad, method of manufacturing the same, and method of manufacturing semiconductor device using the same | SKC索密思株式会社 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-2714716-B1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | SOCPRA SCIENCES SANTE ET HUMAINES S E C (CA) | 2018-04-11 | — | — | EP | disclosed |
| US-20170320829-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170320829-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9650342-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650342-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-1773786-B1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2007100759-A2 | METHOD FOR TREATING COMMON VARIABLE IMMUNODEFICIENCY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2007-06-14 | — | — | US | disclosed |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2007-06-14 | — | — | US | disclosed |
| WO-2007050980-A2 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060189825-A1 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE | 2006-08-24 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004055013-A1 | [1,7]NAPHTHYRIDINES AS PDE4 INHIBITORS | NOVARTIS AG (CH) | 2004-07-01 | — | — | WO | disclosed |